<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511768</url>
  </required_header>
  <id_info>
    <org_study_id>201801001</org_study_id>
    <nct_id>NCT03511768</nct_id>
  </id_info>
  <brief_title>A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms</brief_title>
  <official_title>A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the clinical value of [18F]aluminum
      fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ）
      positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine
      neoplasms (NENs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      18F-AlF-NOTA-octreotide is a radioligand targeting the somatostatin receptor, which is widely
      expressed on the cell surface of NENs. The radioligand can be used for the diagnosis and
      stage of the NENs. A total of 5 volunteers and 60 NEN patients will be subjected to a
      18F-AlF-NOTA-octreotide PET/CT scan. The uptake of 18F-AlF-NOTA-octreotide in organs and
      tumor lesions will be quantified as Standardized Uptake Values (SUVmax/SUVmean).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18F-AlF-NOTA-octreotide PET/CT imaging of patients with Neuroendocrine Neoplasms</measure>
    <time_frame>12 months</time_frame>
    <description>The radioligand 18F-AlF-NOTA-octreotide can be used to visualize neuroendocrine neoplasms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>18F-AlF-NOTA-octreotide PET/CT prognostic factor for overall and disease specific survival</measure>
    <time_frame>24 months</time_frame>
    <description>The uptake of the 18F-AlF-NOTA-octreotide in neuroendocrine neoplasm lesions (quantified as Standard Uptake Values) is associated with overall and disease specific free survival (PFS) neuroendocrine neoplasms</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Neuroendocrine Neoplasm</condition>
  <arm_group>
    <arm_group_label>18F-AlF-NOTA-octreotide PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of the radioligand 18F-AlF-NOTA-octreotide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-AlF-NOTA-octreotide</intervention_name>
    <description>One injection of 18F-AlF-NOTA-octreotide</description>
    <arm_group_label>18F-AlF-NOTA-octreotide PET/CT</arm_group_label>
    <other_name>18F-IMP466</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <description>Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT</description>
    <arm_group_label>18F-AlF-NOTA-octreotide PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically and/or clinically confirmed and/or suspicious of NEN.

          2. Signed informed consent.

        Exclusion Criteria:

          1. Claustrophobia (unable to accept PET/CT scanning)

          2. Pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tingting Long, MD,Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of PET Center,Xiangya Hospital, Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tingting Long, MD,Phd</last_name>
    <phone>+86 13549682646</phone>
    <email>longtingting@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuo Hu, professor</last_name>
    <phone>+86 15874210819</phone>
    <email>hushuo_xy@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of PET Center,Xiangya Hospital,Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tingting Long, MD,Phd</last_name>
      <phone>+86 13549682646</phone>
      <email>longtingting@csu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, Goldenberg DM, Boerman OC. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med. 2010 Mar;51(3):454-61. doi: 10.2967/jnumed.109.066902. Epub 2010 Feb 11.</citation>
    <PMID>20150268</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>18F-AlF-NOTA-octreotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

